Axel Bolte
Founder bij INOZYME PHARMA, INC.
Vermogen: 2 M $ op 31-03-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Steven Gelone | M | 56 |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 10 jaar |
| Glenn Sblendorio | M | 68 | 11 jaar | |
| Daniel Burgess | M | 62 |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA.
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 13 jaar |
| Mark Reisenauer | M | 58 | 1 jaar | |
| Christine Utter | F | 46 | 14 jaar | |
| Chau Khuong | M | 48 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 3 jaar |
| Doug Treco Treco | M | 66 | 4 jaar | |
| David Thompson | M | - | 6 jaar | |
| Sarah Bhagat | M | 38 | 5 jaar | |
| Lynne Sullivan | F | 58 | 4 jaar | |
| Dhaval Desai | M | - | 4 jaar | |
| Geoffrey A. Swire | M | - | 6 jaar | |
| Evelyn Harrison | F | - | 17 jaar | |
| Martin Rexroad | M | - | 11 jaar | |
| Jerome Zeldis | M | 74 | 12 jaar | |
| Stefan Riley | M | - | - | |
| Kathy Galante | F | - | 11 jaar | |
| Ed Mathers Mathers | M | 64 | 7 jaar | |
| David Southwell | M | 63 | 19 jaar | |
| Patrick J. Langlois | M | 78 | 16 jaar | |
| Reinaldo Diaz | M | 70 | 7 jaar | |
| Robert Hopfner | M | 51 | 6 jaar | |
| Theodore Schroeder | M | 69 | 6 jaar | |
| Martin Edwards | M | 68 | 7 jaar | |
| Terry Vance | M | 67 | 13 jaar | |
| Murad Husain | M | - | 10 jaar | |
| Daniel Burgess | M | - |
Tripex Pharmaceuticals LLC
 Tripex Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Tripex Pharmaceuticals LLC provides pharmaceutical services. The company is headquartered in Encinas, CA. | - |
| Keith Westby | M | 49 | 7 jaar | |
| Matthew Winton | M | 46 | 1 jaar | |
| Soo-Jin Kim | M | - | 2 jaar | |
| Amy Sheehan | F | - | 10 jaar | |
| Sanjay Subramanian | M | 48 | 2 jaar | |
| Yves Sabbagh | M | - | 4 jaar | |
| Gayle Gironda | F | - | 3 jaar | |
| Christopher Simms | M | 49 | 3 jaar | |
| Kurt C. Gunter | M | 69 | 2 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| David Garrett | M | 44 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | - |
| Thomas Biancardi | M | - | - | |
| Louis Brenner | M | 54 | 7 jaar | |
| Robert L. Crotty | M | 50 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | - |
| Bruce Peacock | M | 72 | 4 jaar | |
| Mark Corrigan | M | 66 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 4 jaar |
| Samir Chandrakant Patel | M | 62 | 10 jaar | |
| Ralf Schmid | M | 57 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 10 jaar |
| David Guyer | M | 64 | 14 jaar | |
| Adrienne Graves | M | 69 | 5 jaar | |
| George Harrison Talbot | M | 76 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 12 jaar |
| Ruggero Fariello | M | 81 | 8 jaar | |
| Marcio Souza | M | 45 | 6 jaar | |
| Pravin Dugel | M | 60 | 3 jaar | |
| Stephen DiPalma | M | 66 | - | |
| Theresa Natalicchio | F | - | - | |
| Cameron McDonough | M | 53 | 5 jaar | |
| Emily Hill | F | 44 | - | |
| Elyse G. Seltzer | M | 59 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 2 jaar |
| Kurt J. W. Andrews | M | 54 | 9 jaar | |
| Carrie Bourdow | F | 61 | 6 jaar | |
| Allene Diaz | F | 59 | 3 jaar | |
| Stephen Buckley | M | 74 | - | |
| Werner Heilmayer | M | - |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 8 jaar |
| Jane Henderson | F | 58 | 5 jaar | |
| Kourous Rezaei | M | - | 5 jaar | |
| David Carroll | M | 58 | - | |
| Todd Anderman | M | - | - | |
| Anu Bhattacharyya | F | - | - | |
| Stephen Basso | M | 58 | 4 jaar | |
| Christine Ann Miller | F | 48 | 1 jaar | |
| Hervé Guérin | M | 82 | - | |
| Calvin Roberts | M | 71 | 4 jaar | |
| Adam Koppel | M | 54 | 4 jaar | |
| Michael L. Kranda | M | 69 | 12 jaar | |
| Michael Atieh | M | 70 | 2 jaar | |
| Nicholas G. Galakatos | M | 66 | 7 jaar | |
| Michael Ross | M | 75 | 6 jaar | |
| John Peter Wolf | M | 54 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 2 jaar |
| Richard H. Aldrich | M | 69 | 2 jaar | |
| David Chiswell | M | 70 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 10 jaar |
| Helmut Schühsler | M | 65 | 2 jaar | |
| Barbara Wood | F | 62 | 5 jaar | |
| Ian Smith | M | 58 | 1 jaar | |
| Ronald Renaud | M | 55 | 3 jaar | |
| David E. Redlick | M | 73 | 3 jaar | |
| Robert Alexander | M | 54 | 6 jaar | |
| Joseph P. Schlessinger | M | 79 | 5 jaar | |
| André L. Lamotte | M | 75 |
New Medical Technologies AG
| 1 jaar |
| Mark Blumenkranz | M | 73 | 3 jaar | |
| Edward Wholihan | M | 64 | 5 jaar | |
| Thomas Dyrberg | M | 69 | 12 jaar | |
| Henric Bjarke | M | 57 | 7 jaar | |
| Robert Gallotto | M | 59 | 4 jaar | |
| Stephen Kraus | M | 47 | 7 jaar | |
| Andrew Hack | M | 50 | 3 jaar | |
| Clare Kennedy | F | - | - | |
| Kathryn Haviland | F | 48 | 5 jaar | |
| Manal Morsy | M | - | 5 jaar | |
| Chip Baird | M | 52 | 10 jaar | |
| Robert Spiegel | M | 73 | 5 jaar | |
| Yujiro Hata | M | 49 | 8 jaar | |
| Langdon L. Miller | M | 70 | 7 jaar | |
| Allison Luo | M | 50 | - |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 83 | 83.00% |
| Oostenrijk | 12 | 12.00% |
| Ierland | 9 | 9.00% |
| Italië | 3 | 3.00% |
| Zwitserland | 1 | 1.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Axel Bolte
- Persoonlijk netwerk
